Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock
April 24, 2018 16:01 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (OTCQB:ELOX) today announced that it intends to offer and sell, subject to market and other conditions,...
Eloxx Pharmaceuticals Announces that Two Abstracts for ELX-02 Have Been Accepted for Presentation at the 41st European Cystic Fibrosis Conference
April 18, 2018 11:30 ET
|
Eloxx Pharmaceuticals
ELX-02 is an investigational, novel translational read-through inducing drug designed to restore synthesis of full-length functional proteins Late Breaker evaluation of ELX-02 in cystic fibrosis...
Eloxx Pharmaceuticals Reports Full Year 2017 Financial and Operating Results and Provides Business Update
March 19, 2018 07:00 ET
|
Eloxx Pharmaceuticals
Company to host webcast and conference call on Tuesday, March 20, 2018 at 8 am ET Management to discuss recent data and progress on development plans WALTHAM, Mass., March 19, 2018 (GLOBE NEWSWIRE)...
Eloxx Pharmaceuticals To Present at the Cowen and Company 38th Annual Health Care Conference
March 06, 2018 13:00 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELOX) a clinical-stage biopharmaceutical company developing novel read-through drug candidates that are...
Eloxx Pharmaceuticals Appoints Biotech Leader, Dr. Jasbir Seehra, Co-founder of Acceleron Pharma, to Board of Directors
February 28, 2018 13:01 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELOX) (Other OTC:SVOND) a clinical-stage biopharmaceutical company developing novel read-through drug...
Eloxx Pharmaceuticals Announces a Scientific Presentation on its Lead Product Candidate, ELX-02, at the 14th Annual WORLDSymposium™ 2018 and Participation in Two Investor Events
February 07, 2018 07:52 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELOX) a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are...
Eloxx Pharmaceuticals Chairman and CEO Robert Ward to Participate in a Panel Discussion at the Biotech Showcase 2018 Conference
January 04, 2018 11:39 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (OTC:SVOND), a clinical-stage biopharmaceutical company developing novel small molecule medicines to treat...
UPDATE -- Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer
December 27, 2017 08:56 ET
|
Eloxx Pharmaceuticals
Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Lead The Company’s Strategy, Vision and Execution WALTHAM,...
Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer
December 27, 2017 08:30 ET
|
Eloxx Pharmaceuticals
Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Lead The Company’s Strategy, Vision and Execution WALTHAM,...
Eloxx Pharmaceuticals Completes Acquisition Transaction with Sevion Therapeutics
December 22, 2017 08:37 ET
|
Eloxx Pharmaceuticals
Company to focus on advancing the clinical development of ELX-02, a disease-modifying therapy for genetic diseases caused by nonsense mutations WALTHAM, Mass., REHOVOT, Israel, and SAN DIEGO, Dec. ...